Dr. Abel Jarell reviews findings from a poster on the 31-GEP test’s role in identifying CNS metastasis risk in patients with stage I–II cutaneous melanoma.
Topics Covered:
Explore Related Resources:
Evaluating Melanoma Survival Stratification and Gene Testing
Harrison Nguyen, MD, MBA, MPH, FAAD, the managing director of Harrison Dermatology and Research Group and clinical assistant professor of dermatology at the University of
Dr. Moody reviews findings from a poster presented at the 2025 Fall Clinical Dermatology Conference, highlighting the clinical utility of the 31-gene expression profile (31-GEP)
Dr. Skupsky outlines practical approaches to evaluating atypical pigmented lesions, emphasizing how ancillary testing can support clinical decision-making and improve diagnostic accuracy. Her discussion focuses
Dr. Rizzo presents research from the 2025 AAD Annual Meeting demonstrating the real-world impact of the 31-gene expression profile (31-GEP) test in patients with cutaneous
